AR086824A1 - Composicion oftalmica que comprende un mediador lipido antiinflamatorio esterificado y metodo de tratamiento - Google Patents

Composicion oftalmica que comprende un mediador lipido antiinflamatorio esterificado y metodo de tratamiento

Info

Publication number
AR086824A1
AR086824A1 ARP120102365A ARP120102365A AR086824A1 AR 086824 A1 AR086824 A1 AR 086824A1 AR P120102365 A ARP120102365 A AR P120102365A AR P120102365 A ARP120102365 A AR P120102365A AR 086824 A1 AR086824 A1 AR 086824A1
Authority
AR
Argentina
Prior art keywords
ophthalmic composition
inflammatory lipid
composition
estrified
treatment method
Prior art date
Application number
ARP120102365A
Other languages
English (en)
Original Assignee
Johnson & Johnson Vision Care
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Vision Care filed Critical Johnson & Johnson Vision Care
Publication of AR086824A1 publication Critical patent/AR086824A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Eyeglasses (AREA)

Abstract

Reivindicación 1: Una composición oftálmica para el tratamiento de condiciones oculares; la composición comprende: un éster o una amida de un mediador lípido antiinflamatorio que es un producto de reacción del mediador lípido antiinflamatorio y un alcohol monohídrico o una amina; y un sistema de suministro acuoso; en donde la mayoría del mediador lípido antiinflamatorio se encuentra presente en una forma de éster. Reivindicación 29: Una preparación estéril, solución, gel, ungüento, emulsión o tira para la administración al ojo o a una lente de contacto que comprende la composición de la reivindicación 1. Reivindicación 30: Un método para preparar una composición oftálmica para el tratamiento de condiciones oculares; el método comprende proporcionar la composición de la reivindicación 1 y formar la composición oftálmica.
ARP120102365A 2011-06-30 2012-06-29 Composicion oftalmica que comprende un mediador lipido antiinflamatorio esterificado y metodo de tratamiento AR086824A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161503158P 2011-06-30 2011-06-30
US13/495,049 US10383839B2 (en) 2011-06-30 2012-06-13 Esters for treatment of ocular inflammatory conditions

Publications (1)

Publication Number Publication Date
AR086824A1 true AR086824A1 (es) 2014-01-22

Family

ID=47391255

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP120102366A AR086825A1 (es) 2011-06-30 2012-06-29 Composicion oftalmica que comprende un mediador lipido antiinflamatorio esterificado y metodo de tratamiento
ARP120102365A AR086824A1 (es) 2011-06-30 2012-06-29 Composicion oftalmica que comprende un mediador lipido antiinflamatorio esterificado y metodo de tratamiento

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP120102366A AR086825A1 (es) 2011-06-30 2012-06-29 Composicion oftalmica que comprende un mediador lipido antiinflamatorio esterificado y metodo de tratamiento

Country Status (14)

Country Link
US (7) US8865685B2 (es)
EP (3) EP2726058B1 (es)
JP (4) JP6352177B2 (es)
KR (4) KR102203310B1 (es)
CN (5) CN108272783B (es)
AR (2) AR086825A1 (es)
AU (10) AU2012275759A1 (es)
BR (2) BR112013033941A2 (es)
CA (2) CA2840152C (es)
ES (1) ES2743174T3 (es)
PL (1) PL3556346T3 (es)
RU (8) RU2707961C2 (es)
TW (4) TWI633883B (es)
WO (2) WO2013003113A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110478342A (zh) 2012-05-10 2019-11-22 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
MA41912A (fr) * 2015-04-07 2018-02-13 Hyalblue S R L Esters de glycosaminoglycane, procédés pour leur préparation et leur utilisation dans des formulations à usage ophtalmique
WO2017025588A1 (en) * 2015-08-11 2017-02-16 Eyesiu Medicines B.V. Pegylated lipid nanoparticle with bioactive lipophilic compound
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
US11129862B2 (en) 2017-08-30 2021-09-28 Johnson & Johnson Consumer Inc. Ophthalmic compositions
CN108096181A (zh) * 2018-02-05 2018-06-01 西安医学院 Dha、epa在制备治疗干眼症的口服药物的应用
NO345574B1 (en) * 2018-06-19 2021-04-26 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
US11077150B2 (en) * 2018-10-09 2021-08-03 Massoumeh Kharazmi Methods and compositions for treatment of eye conditions
US20220226270A1 (en) * 2019-04-04 2022-07-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
CN110947088A (zh) * 2019-12-06 2020-04-03 广州新济薇娜生物科技有限公司 护眼组合贴片及其制备方法
BR112023002449A2 (pt) * 2020-08-10 2023-03-28 Bausch Lomb Ireland Ltd Soluções de embalagem
US20220187620A1 (en) * 2020-12-15 2022-06-16 Coopervision International Limited Oleic acid-releasing contact lens
US12012238B2 (en) * 2021-05-26 2024-06-18 Bausch + Lomb Ireland Limited Packaging solutions
WO2023049791A1 (en) * 2021-09-22 2023-03-30 The Trustees Of Columbia University In The City Of New York Delivery systems for bioactive lipids

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577446A (en) 1968-09-09 1971-05-04 American Home Prod Phosphatidylalkanolamine derivatives
US4330383A (en) 1978-07-18 1982-05-18 Polymer Technology Corporation Dimensionally stable oxygen permeable hard contact lens material and method of manufacture
US4495313A (en) 1981-04-30 1985-01-22 Mia Lens Production A/S Preparation of hydrogel for soft contact lens with water displaceable boric acid ester
JPS60110855A (ja) 1983-11-17 1985-06-17 Toshiba Corp 装飾部品の製造方法
JPS6123860A (ja) 1984-07-12 1986-02-01 Yamaha Motor Co Ltd 多気筒エンジンの給気装置
US5032392A (en) 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
DE3704825A1 (de) 1987-02-16 1988-08-25 Froelich Juergen Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US4889664A (en) 1988-11-25 1989-12-26 Vistakon, Inc. Method of forming shaped hydrogel articles including contact lenses
US5039459A (en) 1988-11-25 1991-08-13 Johnson & Johnson Vision Products, Inc. Method of forming shaped hydrogel articles including contact lenses
US4915974A (en) 1989-02-17 1990-04-10 Nabisco Brands, Inc. Polyvinyl oleate as a fat replacement
SE9101642D0 (sv) 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
JPH06123860A (ja) 1992-10-09 1994-05-06 Tokyo Keikaku:Kk 酸素透過性ハードコンタクトレンズ
US5472703A (en) * 1993-03-02 1995-12-05 Johnson & Johnson Vision Products, Inc. Ophthalmic lens with anti-toxin agent
US5337888A (en) * 1993-09-01 1994-08-16 Morrison Robert J Contact lens case
US5460802A (en) * 1994-07-18 1995-10-24 Minnesota Mining And Manufacturing Company Oral disinfectant for companion animals
US5760100B1 (en) 1994-09-06 2000-11-14 Ciba Vision Corp Extended wear ophthalmic lens
US7468398B2 (en) 1994-09-06 2008-12-23 Ciba Vision Corporation Extended wear ophthalmic lens
DE19511322C2 (de) 1995-03-28 1999-09-02 Mann Gerhard Chem Pharm Fab Sterile Augengele mit einem Gehalt an mittelkettigen Triglyceriden und Verfahren zu deren Herstellung
TW585882B (en) 1995-04-04 2004-05-01 Novartis Ag A method of using a contact lens as an extended wear lens and a method of screening an ophthalmic lens for utility as an extended-wear lens
US6585768B2 (en) 1997-12-02 2003-07-01 Hoya Healthcare Corporation Intraocular lenses and process for the producing molded-in type intraocular lenses
FR2772033A1 (fr) 1997-12-05 1999-06-04 Essilor Int Procede de fabrication d'un materiau polymere transparent resistant au depot de proteines, materiau obtenu par ce procede, lentilles de contact et implants intraoculaires faits de ce materiau
DE69908304T2 (de) 1998-02-11 2004-02-19 Rtp Pharma Corp. Ungesättigte fettsäure und steroide enthaltende kombinationspräparate zur behandlung von entzündungen
US5998498A (en) 1998-03-02 1999-12-07 Johnson & Johnson Vision Products, Inc. Soft contact lenses
US7052131B2 (en) 2001-09-10 2006-05-30 J&J Vision Care, Inc. Biomedical devices containing internal wetting agents
US6087415A (en) 1998-06-11 2000-07-11 Johnson & Johnson Vision Care, Inc. Biomedical devices with hydrophilic coatings
JP2000010055A (ja) 1998-06-19 2000-01-14 Seed Co Ltd 親水性眼用レンズ及びその製造方法
JP3824791B2 (ja) 1998-10-01 2006-09-20 株式会社ニデック 眼内レンズの製造方法
TR200101048T2 (tr) 1998-10-13 2001-07-23 Pharmacia Groningen B.V. Enjekte edilebilir göz-içi lensleri
SE9803481D0 (sv) 1998-10-13 1998-10-13 Pharmacia & Upjohn Ab Photocurable siloxane polymers
US6291519B1 (en) * 1998-10-14 2001-09-18 Novartis Ag Method of preventing damage to eye tissue
AU760960B2 (en) 1998-10-29 2003-05-22 Advanced Medical Optics, Inc. Intraocular lenses made from polymeric compositions
US7297214B2 (en) * 1999-09-03 2007-11-20 Kiyohito Ishida Free cutting alloy
US6645978B1 (en) * 1999-11-09 2003-11-11 Alcon, Inc. Lipoxin A4 and its analogs for the treatment of dry eye
WO2001046134A1 (en) 1999-12-22 2001-06-28 Alcon Universal Ltd. 6-KETO PROSTAGLANDIN F1α AND ANALOGS FOR TREATING DRY EYE
JP4434397B2 (ja) * 1999-12-28 2010-03-17 株式会社シード 軟質眼用レンズ
IL134240A0 (en) 2000-01-27 2001-04-30 Senyorina Ltd Inositol derivatives and their pharmaceutical use
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US6506412B2 (en) 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US6531432B2 (en) 2000-12-07 2003-03-11 Johnson & Johnson Vision Care, Inc. Contact lens packaging solutions
WO2002096871A1 (en) 2001-05-30 2002-12-05 Yeda Research And Development Co. Ltd. Allylmercaptocaptopril compounds and uses thereof
CA2469647C (en) * 2001-12-12 2011-02-15 Daniel G. Dueppen Extraction and winterization of lipids from oilseed and microbial sources
AU2003238240A1 (en) 2002-06-17 2003-12-31 Resolvyx Pharmaceuticals ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
EP1535617A1 (en) 2002-07-02 2005-06-01 Wakamoto Pharmaceutical Co., Ltd. Remedy or preventive for keratoconjunctival epithelial cell injury
US20050124699A1 (en) * 2002-07-02 2005-06-09 Wakamoto Pharmaceutical Co., Ltd. Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells
AU2003259145A1 (en) 2002-07-17 2004-02-02 Spencer P. Thornton Treatment for dry eye syndrome
US20060251685A1 (en) 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
CA2467410A1 (en) 2003-05-27 2004-11-27 Synphora Ab Method for treatment of glaucoma and ocular hypertension with prostaglandin analgoues without melanogenic side-effect
FR2857770B1 (fr) * 2003-07-18 2005-10-21 Valois Sas Indicateur de doses ameliore pour dispositif de distribution de produit fluide.
US20050103466A1 (en) 2003-11-19 2005-05-19 Landry Kenneth D. Refrigerator-oven
US20050220742A1 (en) 2004-03-31 2005-10-06 Breen Ed V Compositions and methods for maintaining eyelid hygiene
CA2572344A1 (en) * 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
US20070265341A1 (en) 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
US7553860B2 (en) 2006-06-14 2009-06-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US20070293410A1 (en) * 2006-06-15 2007-12-20 Surowiak Richard J Contact lens and method for preventing contact lens intolerance
WO2008058274A2 (en) 2006-11-09 2008-05-15 Children's Medical Center Corporation Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization
GB0623299D0 (en) 2006-11-22 2007-01-03 Sauflon Cl Ltd Contact lens
US20080161275A1 (en) 2006-12-05 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
RU2336851C1 (ru) 2007-06-21 2008-10-27 Эрнест Витальевич Бойко Мягкая контактная линза
US10105441B2 (en) 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
TWI551305B (zh) 2007-08-31 2016-10-01 諾華公司 相對黏稠封裝溶液之用途
CN101888839B (zh) * 2007-10-12 2013-03-20 雷索维克斯药品公司 治疗眼睛病症的omega-3脂肪酸、羟基多不饱和脂肪酸、脂氧素类化合物或脂氧化物类化合物
US7884141B2 (en) 2007-11-14 2011-02-08 Bausch & Lomb Incorporated Biomedical devices
JP5355588B2 (ja) * 2007-12-20 2013-11-27 ノバルティス アーゲー コンタクトレンズを製造する方法
US20100105772A1 (en) 2008-04-25 2010-04-29 Serhan Charles N Use of novel lipid mediators to inhibit angiogenesis
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
TWI506333B (zh) 2008-12-05 2015-11-01 Novartis Ag 用以傳遞疏水性舒適劑之眼用裝置及其製造方法
WO2010103402A1 (en) 2009-03-09 2010-09-16 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form and a surfactant, and methods and uses thereof
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
US9480645B2 (en) 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
JP6123860B2 (ja) 2015-09-17 2017-05-10 王子ホールディングス株式会社 ベルト型使い捨ておむつ
JP2017195808A (ja) * 2016-04-27 2017-11-02 三菱ケミカル株式会社 カンゾウ属植物の育成方法

Also Published As

Publication number Publication date
JP2019178150A (ja) 2019-10-17
US20200206178A1 (en) 2020-07-02
JP2014518262A (ja) 2014-07-28
AU2017204759A1 (en) 2017-07-27
JP2018065792A (ja) 2018-04-26
CN103796635A (zh) 2014-05-14
AU2019203920A1 (en) 2019-06-20
KR102203310B1 (ko) 2021-01-15
AU2017204838B2 (en) 2019-03-21
US8865685B2 (en) 2014-10-21
EP3556346B1 (en) 2021-10-13
RU2017125922A3 (es) 2019-01-31
EP2726058B1 (en) 2019-06-19
RU2017142720A3 (es) 2019-06-07
TW201315464A (zh) 2013-04-16
WO2013003114A8 (en) 2013-07-25
AU2012275760B2 (en) 2017-08-03
BR112013033941A2 (pt) 2017-02-14
EP3556346A1 (en) 2019-10-23
CN107260716A (zh) 2017-10-20
CA2840152A1 (en) 2013-01-03
KR20140146037A (ko) 2014-12-24
AU2012275759A1 (en) 2014-01-23
CA2840152C (en) 2021-06-08
US11311510B2 (en) 2022-04-26
RU2673230C1 (ru) 2018-11-23
RU2014102958A (ru) 2015-08-10
US20190328698A1 (en) 2019-10-31
AU2019204333A8 (en) 2019-08-22
CN108272783A (zh) 2018-07-13
AU2022228206A1 (en) 2022-10-06
TWI587857B (zh) 2017-06-21
TW201906596A (zh) 2019-02-16
CA2840155C (en) 2021-09-14
CA2840155A1 (en) 2013-01-03
KR20140048947A (ko) 2014-04-24
JP6675361B2 (ja) 2020-04-01
AU2017204759B2 (en) 2019-03-07
AU2012275760A1 (en) 2014-01-23
AU2017204838B9 (en) 2021-09-09
AR086825A1 (es) 2014-01-22
JP6352177B2 (ja) 2018-07-04
RU2018133283A3 (es) 2020-03-20
CN103813783A (zh) 2014-05-21
KR20190108650A (ko) 2019-09-24
US20130005691A1 (en) 2013-01-03
RU2747953C2 (ru) 2021-05-17
KR102022838B1 (ko) 2019-09-20
PL3556346T3 (pl) 2022-01-31
KR102023326B1 (ko) 2019-11-04
AU2019203920B2 (en) 2020-05-14
RU2018136873A3 (es) 2020-04-20
RU2018133283A (ru) 2020-03-20
JP2014518261A (ja) 2014-07-28
US10588887B2 (en) 2020-03-17
AU2017204838A1 (en) 2017-08-03
US20200222357A1 (en) 2020-07-16
US10383839B2 (en) 2019-08-20
RU2627438C2 (ru) 2017-08-08
RU2017125922A (ru) 2019-01-31
US20210379005A1 (en) 2021-12-09
TW201315465A (zh) 2013-04-16
RU2640506C9 (ru) 2018-05-11
TW201818920A (zh) 2018-06-01
WO2013003114A1 (en) 2013-01-03
US11096919B2 (en) 2021-08-24
US20130005805A1 (en) 2013-01-03
TWI633883B (zh) 2018-09-01
WO2013003113A1 (en) 2013-01-03
CN108969471A (zh) 2018-12-11
KR20190108648A (ko) 2019-09-24
AU2020204211A1 (en) 2020-07-16
AU2020281097A1 (en) 2021-01-07
EP2726061A1 (en) 2014-05-07
EP2726058A1 (en) 2014-05-07
AU2019204333A1 (en) 2019-07-11
US20140364400A1 (en) 2014-12-11
TWI713867B (zh) 2020-12-21
BR112013034054A2 (pt) 2017-02-07
AU2022202729A1 (en) 2022-05-19
RU2640506C2 (ru) 2018-01-09
RU2019137026A (ru) 2021-05-19
RU2018136873A (ru) 2020-04-20
CN108272783B (zh) 2020-11-17
ES2743174T3 (es) 2020-02-18
RU2014102996A (ru) 2015-08-10
EP2726061B1 (en) 2017-02-22
JP6282586B2 (ja) 2018-02-21
RU2017142720A (ru) 2019-06-07
RU2707961C2 (ru) 2019-12-03

Similar Documents

Publication Publication Date Title
AR086824A1 (es) Composicion oftalmica que comprende un mediador lipido antiinflamatorio esterificado y metodo de tratamiento
BR112014009146A8 (pt) formulações de etanercepte estabilizadas com aminoácidos
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
BR112015009228A8 (pt) Formulação farmacêutica líquida estéril e forma de dosagem intraocular oftálmica líquida estéril para injeção
BR112013019026A2 (pt) formulações farmacêuticas incluindo um composto amina
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
CO7141413A2 (es) Proceso para la preparación de derivados de 2-(1-hidroxi-alquil)-cromen-4-ona ópticamente puros y opcionalmente sustituidos y su uso en la preparación de compuestos farmacéuticos
CR20140053A (es) Formulaciones de ácido desoxicólico y sales del mismo
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
BR112015030431A2 (pt) formulação de liberação modificada
PE20151208A1 (es) Composiciones de diclofenaco
BR112013030145A2 (pt) processo para preparação de ácido metacrílico
AR097997A1 (es) Composición farmaceutica de ibuprofeno y tramadol para uso oftálmico
BR112014010509A2 (pt) sistema de dispensa vaginal osmoticamente ativo
PE20130374A1 (es) Composicion farmaceutica que comprende ibuprofeno
CO6781464A2 (es) Péptidos del veneno de escorpión rhopalorus junceus y composición farmacéutica
CO2019002663A2 (es) Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantes
EP4364810A3 (en) Topical formulations and uses thereof
WO2014204357A3 (ru) Лекарственное средство для лечения кератоконуса
BR112014002712A2 (pt) método para tratamento da esquizofrenia
MX2013013286A (es) Formulación y método de preparación para obtener soluciones oftálmicas derivadas de quinolonas y una enzima proteasa con propiedades antinflamatorias y analgésicas.
BR112015028677A2 (pt) corantes ácidos, processo para a produção dos mesmos e seus usos
RU2012120961A (ru) Способ лечения глаукоматозной оптической нейропатии
CU20090151A7 (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas

Legal Events

Date Code Title Description
FB Suspension of granting procedure